227180-19-0

Basic information

• Product Name: N-(6-Methoxy-pyridin-3-yl)-2,2-dimethyl-propionamide
• Synonyms: N-(6-Methoxy-pyridin-3-yl)-2,2-dimethyl-propionamide;N-(6-methoxy-3-pyridinyl)-2,2-dimethylPropanamide
• CAS NO: 227180-19-0
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.25694
• Mol File: 227180-19-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 355.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.100±0.06 g/cm3(Predicted)
• PKA: 13.60±0.70(Predicted)
• CAS DataBase Reference: N-(6-Methoxy-pyridin-3-yl)-2,2-dimethyl-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-Methoxy-pyridin-3-yl)-2,2-dimethyl-propionamide(227180-19-0)
• EPA Substance Registry System: N-(6-Methoxy-pyridin-3-yl)-2,2-dimethyl-propionamide(227180-19-0)

Safety Data

• Hazardous Substances Data: 227180-19-0(Hazardous Substances Data)

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 227180-22-5 5-amino-2-methoxy-4-<2-(1,1,1-trimethylsilyl)-1-ethynyl>pyridine 
• 227180-23-6 3-formyl-5-methoxy-1H-pyrrolo<2,3-c>pyridine 
• 227180-21-4 4-iodo-6-methoxypyridin-3-ylamine 
• 227180-20-3 2,2-dimethyl-N-<4-iodo-6-methoxy-3-pyridinyl>propanamide 

Relevant articles and documents

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

Synthesis of new melatoninergic ligands including azaindole moiety

A novel series of melatonin analogues, based on the azaindole nucleus is described. These compounds are prepared in several steps directly from the commercial available 7-azaindole or from substituted amino-, iodo- or/and nitropyridines using a catalysed palladium reaction or vicarious nucleophilic substitution of hydrogen (VNS) in order to elaborate the 6-, 5- and 4- azaindole derivatives respectively.